Both the firms should collectively practice a Stage- Gate methodology of measuring the progress of the technological innovation. FDA approval is a long process 5 years which would affect future business strategies.
Forming a joint venture with the biotech firm Biopart, equally sharing all future costs and profits. Furthermore they miss an opportunity to have some profit with this product. Although the chances are low, there is also 3 risk that the product may fail to capture the market just after getting an approval from the FDA.
All the costs associated with the operations, marketing and commercialization of the product would be solely borne by Pharmacol. Abgenix were inexperienced about the process development, manufacturing and marketing steps.
It also lacks the knowledge and experience of managing the regulatory processes to btain the FDA approval in the process of commercialization of its drugs. Of these Pharmacol and Biopart were of interest to Abgenix. From this deal however, Abgenix will get a larger share of the of sales.
Thus, having XenoMouse as a resource renders Abgenix xenomouse essay a vast array of antibody therapies, the development of which can either be undertaken in-house or licensed to a corporate collaborator for payment of, typically, an upfront fee, early development fees as well as royalties following market launch of a given treatment.
The profitability of the firm by collaborating with either of these two firms from a solely Net-Present-VaIue point of view, will depend on the approval by the FDA. The disadvantages of having a partner are as follows: Owing to the large market share in the treatment of cancer refer Financial Analysis it makes a logical sense for Abgenix to focus on developing and commercializing ABX-EGF as an antibody based product to eradicate cancer.
More Essay Examples on Pharmacology Rubric Before testing in humans was permitted, Preclinical Trials had to show sufficient evidence of safety and desired biological activity to gain FDA approval. Since all the aforementioned products are derivatives of XenoMouse based antibody generation, Abgenix should go for a market segmentation in coming up with the best strategy for ll of its products.
However, when to partner is one more key question: Proprietary product development programs were doing Step 3 and Step 4 and some but not all of Step 5.
Abgenix would bear little risk and receive license royalties. Utilizing XenoMouse, Abgenix has a competitive advantage in antibody development to specific disease targets, which normally are discovered and validated by Research and Technology Organisations RTOs or small technology firms.
Abgenix would bear moderate risk but split profits. Although having negative net results until year 6, if we look at NPV it is much better option than the first one. Another risk involved in partnering with Biopart is the probability of the product gaining market acceptance, which is in coherence with the previous stated risk.
The invention seemed to change the paradigm of cancer treatment. Abgenix has the in-house capabilities of carrying the preclinical testing up to the end of phase II, when the value perceived by the buyer substantially increases. Thus, Abgenix capabilities do not reach beyond phase II clinical trials, for which reason the company does not have a resource base capable of commercializing an antibody drug, e.
The joint venture entails co-development work in phase II, whereas Biopart will take the lead in subsequent phases including in what concerns commercialization activities.
When we recall them; these two businesses were technology licensing of XenoMouse and proprietary product development programs. Testing then proceeded through three phases with humans.
Abgenix was in the eve of its big decision. Obtaining an FDA approval is a risk that is inherent in the process of drug commercialization and the best way to deal with it is to iteratively repeat the drug development and testing process until the product receives an FDA approval.
Establishing a joint venture with Biopart Relative to Pharmacol, Biopart is a small industry player, which is not able to carry out an equivalent marketing effort and thus generate the same sales of a potential commercialization of ABX-EGF.
The market for cancer drugs was not a Blue Ocean, and had many competitors namely Herceptin, Rituxan etc. FDA approval can be received only after Phase 3 becomes successful.
The partnership with either of the above two firms would be focussed around Cancer-treatment. As discussed before, they would incur huge Operating and marketing costs which is not in the interests of the investors, as it will hamper the timeline required to become profitable. The core competency of Biopart as a biotechnology company is, on the treatment and study of Cancer Oncology.
Also, Abgenix being a relatively new firm in the field of biotechnology, lacks the necessary complementary assets including capabilities for mass manufacturing of the product, necessary marketing expertise, sales force for marketing and the relevant reputation needed for market penetration.
If Abgenix partners with Pharmacol, it would completely lose its power, over the knowledge and intellectual property it had acquired. Because of its diverse portfolio, there is a possibility that Pharmacol may decide to neglect ABX-EGF in the event of it not being successful.
The pre-clinical trials of ABXEGF, proved the potential it has, in eradicating preformed human cancer tumors injected in all the mice used for testing.
Success of HuMabMouse based products thus, can directly affect the sales of XenoMouse based products. Due to its recently successful IPO, Abgenix has sufficient funds to venture into a merger which promises greater returns.
In addition to these royalty fees, Pharmacol would make some initial payments during clinical testing, which offset the potential risk of failure. Pharmacol, Biopart and go it alone.1) How do you think Abgenix can best exploit the Xeno Mouse? What should they do now?
2) Who else could capture value from the Xeno Mouse? PLACE THIS ORDER OR A SIMILAR ORDER WITH US TODAY AND GET AN AMAZING DISCOUNT 🙂.
Abgenix Case Study. A - Abgenix Case Study introduction. Introduction: Abgenix was a company founded in California who had a unique method for generating antibodies useful in treating a number of diseases, one of which was cancer.
They named this unique method XenoMouse.
Abgenix Essays: OverAbgenix Essays, Abgenix Term Papers, Abgenix Research Paper, Book Reports. ESSAYS, term and research papers available for UNLIMITED access. XenoMouse lived at Abgenix in Frernont, California, just across the Dunbarton Bridge frorn Silicon Valley's farned Highway While no product based on the genetically engineered XenoMouse had yet reached the market, he was the source of the company's near $3 billion rnarket capitalization of March 3L, If it does this successfully them Abgenix will, in addition to the initial payments, receive high royalty rates from the sales.
The hand-in option A hand-in is an agreement between two companies where two companies combine. "Abgenix And The Xenomouse" Essays and Research Papers Abgenix And The Xenomouse Introduction: Abgenix was a company founded in California who had a unique method for generating antibodies useful in treating a number of .Download